Waldenström Macroglobulinemia, An Issue of Hematology/Oncology Clinics of North America

1st Edition, Volume 37-4 - June 30, 2023
Editors: Jorge J Castillo, Prashant Kapoor, Shayna Sarosiek
Language: English
Hardback ISBN:
9 7 8 - 0 - 4 4 3 - 1 8 2 9 8 - 3
eBook ISBN:
9 7 8 - 0 - 4 4 3 - 1 8 2 9 9 - 0

In this issue of Hematology/Oncology Clinics, guest editors Drs. Jorge J. Castillo, Prashant Kapoor, and Shayna Sarosiek bring their considerable expertise to the topic of… Read more

Waldenström Macroglobulinemia, An Issue of Hematology/Oncology Clinics of North America

Purchase options

Info / Buy

LIMITED OFFER

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code needed.

Institutional subscription on ScienceDirect

Request a sales quote

In this issue of Hematology/Oncology Clinics, guest editors Drs. Jorge J. Castillo, Prashant Kapoor, and Shayna Sarosiek bring their considerable expertise to the topic of Waldenström Macroglobulinemia. Top experts in the field provide a focused update on the biology, diagnosis and management, and novel therapies for patients with Waldenström macroglobulinemia, a rare blood cell cancer characterized by an excess of abnormal white blood cells in the bone marrow.

Cover image
Title page
Table of Contents
Copyright
Contributors
Forthcoming Issues
Preface
Clinical Implications of Genomic Profile in Waldenström Macroglobulinemia
Key points
Introduction
Summary
Clinics care points
Disclosures
Frontline Management of Waldenström Macroglobulinemia with Chemoimmunotherapy
Key points
Introduction
Alkylating agent-based regimens
Purine-analog based regimens
Impact of underlying Waldenström macroglobulinemia-related somatic mutations on patient outcomes with chemoimmunotherapy
Clinics care points
Conflict of interest
Proteasome Inhibitor-Based Regimens in the Frontline Management of Waldenström Macroglobulinemia
Key points
Introduction
Proteasome inhibitors
New proteasome inhibitors
Summary
Clinics care points
BTK Inhibitors in the Frontline Management of Waldenström Macroglobulinemia
Key points
Introduction
Current evidence with BTK inhibitors as initial therapy for symptomatic Waldenström macroglobulinemia
Summary
Clinics care points
Disclosure
Future Directions in the Frontline Management of Waldenström Macroglobulinemia
Key points
Asymptomatic patients
Patients in need of treatment
Emerging treatments
The vision of future front-line treatment in Waldenström macroglobulinemia
Author disclosures
The Management of Relapsed or Refractory Waldenström’s Macroglobulinemia
Key points
Introduction
Definition relapsed and refractory Waldenström’s macroglobulinemia
Current treatment options for relapsed/refractory Waldenström’s macroglobulinemia
Combinations with conventional chemotherapy
Other emerging treatments
Which therapy should we choose?
Clinics care points
Disclosure
Funding
Conflicts of interest
Novel Agents in Waldenström Macroglobulinemia
Key points
Introduction
Bruton tyrosine kinase inhibitors
Bruton tyrosine kinase degraders
Bruton tyrosine kinase inhibitor combinations
C-X-C chemokine receptor type 4 targeting agents
Other targeted agents
Immunotherapies
Summary
Clinics care points
Contributions
Disclosures
Investigation and Management of Immunoglobulin M– and Waldenström-Associated Peripheral Neuropathies
Key points
Introduction
Incidence and prevalence
Prognosis
Specific immunoglobulin M autoantibody reactivity
Approach to diagnosis
Treatment summary
Summary
Clinics care points
Disclosure
Evaluation and Management of Bing–Neel Syndrome
Key points
Introduction
Epidemiology
Clinical presentation
Diagnosis
Treatment
Treatment of ocular Bing–Neel syndrome
Prognosis
Summary
Disclosure
Evaluation and Management of Disease Transformation in Waldenström Macroglobulinemia
Key points
Introduction and historical perspectives
Discussion
Summary
Clinics care points: recommendations for management of histologic transformation in Waldenström macroglobulinemia
Authorship
Management of Waldenström Macroglobulinemia in Limited-Resource Settings
Key points
Introduction
Methods
Epidemiology of Waldenström macroglobulinemia
Diagnosis, staging, and risk assessment
Management
Final recommendations of the expert panel
Clinics care points

Life Sciences

Physical Sciences & Engineering

Social Sciences & Humanities

Health

Waldenström Macroglobulinemia, An Issue of Hematology/Oncology Clinics of North America

Purchase options

Save 50% on book bundles

Institutional subscription on ScienceDirect

Prashant Kapoor

Shayna Sarosiek